This website is intended for US healthcare professionals
Are you a healthcare professional in the US?
Yes
No

Proud to partner with the Veterans Administration

The Department of Veterans Affairs reports that veterans are more likely to experience migraine than civilians.1

The Global Burden of Disease (GBD) study of 2016 ranks migraine, in years of life lived with disability, as the second most disabling disorder globally.2

Nerivio VA Ordering Information
Prescribe Nerivio using this form. Available also via e-prescription*
1
Send the prescription to ProCare Rx
2
ProCare Rx will deliver Nerivio directly to your patient
3
Nerivio really helped me!
Nerivio

For Teens

FDA
Approved
Treat &
Prevent
Ages
8 & Up

To order Nerivio, please follow these steps:

1. Medical Provider submits order to Prosthetics/Pharmacy
Product
Description
# of devices
A. Item #: Nerivio 3
Three Months of Treatment
3
B. Item #: Nerivio 6
Six Months of Treatment
6
C. Item #: Nerivio 12
Twelve Months of Treatment
12
FSS #: 36F79721D0103
2. Prosthetics sends the PO for Nerivio

ORDERING CONTACT:

Veterans Medical Distributors, Inc.

Email: office@vmdinc.com

Phone: (561)588-3222

High five for freedom from medication complications and side effects

Drug-free and non-addictive
No systemic side effects
No pills, no needles
No risk of overuse
Use alone or alongside medication 

Drug-free, easy-to-use, non-invasive wearable device to treat and prevent migraine

EFFECTIVE

66.7% of patients  found relief from their migraine pain at 2 hrs post treatment.(3)
4 migraine days reduction when used every other day.(5)

SAFE

96.4% of patients studied did not report any device related side effects.(3)
‍0 device-related adverse events reported in pivotal prevention trial. (5)

EASY-TO-USE

89.7% of patients opted to treat with REN (Nerivio) to avoid medication use.(4)

Sources

  1. americanmigrainefoundation.org
  2. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954-976. doi:10.1016/S1474-4422(18)30322-3
  3. Yarnitsky D, Dodick DW, Grosberg BM, Burstein R, Ironi A, Harris D, Lin T, Silberstein SD. Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Headache. 2019;59(8): 1240-1252
  4. Marmura MJ, Lin T, Harris D, lroni A, Rosen NL. Incorporating Remote Electrical Neuromodulation (REN) Into Usual Care Reduces Acute Migraine Medication. Use: An Open-Label Extension Study. Frontiers in Neurology. 2020; 11 :226
  5. Tepper SJ, et al. Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial. Headache. 2023. doi: 10.1111/head.14469.

‍